HIV Provider-Patient Communication Regarding CVD Risk
The AIDS Treatment for Life International Survey (ATLIS) was a multicountry, comparative, cross-sectional survey of people living with HIV in 5 global regions: North America (the United States); Latin American (Brazil); Europe (France, Germany, Italy, Russia, Spain, and the United Kingdom); Asia (Australia and Korea); and Africa (Cote d'Ivoire and South Africa) in January to March 2010, with 100 to 200 enrollees per country. The project was initiated and coordinated by the International Association of Physicians in AIDS Care and governed by an ATLIS Task Force composed of HIV experts from 5 continents. The ATLIS survey fieldwork was conducted from January to March 2010 by Kantar Health, a global health research organization.
A standardized approach to patient recruitment, sampling frame, and recruitment setting was complemented by country-specific adaptations to account for local circumstances. Study eligibility included age more than 17 years, diagnosis of HIV or AIDS, and treatment with ART within the past 5 years. Patients were recruited in health care facilities and in community-based organizations and support groups and administered a 40-minute survey via direct interview or telephone encounter or an online self-administered questionnaire. Monetary incentives were offered to respondents for completion of interviews where customary and varied by country, depending on local practice. The ATLIS protocol, questionnaire, and patient recruitment materials were reviewed and approved by Essex Institutional Review Board, Lebanon, New Jersey, as well as by the research ethics review board in each of the countries involved.
To explore the differences in CVD risk, higher risk of CVD was defined as a diagnosis of heart disease or diabetes or both, or age more than 50, diagnosis of hypercholesterolemia or hypertension, smoking history, and obesity. A lower risk of CVD was defined by no history of heart disease or diabetes and not more than 1 CVD risk factor reported previously.
Data were entered into the study database via the Internet directly following the interviews. Data analyses were performed using STATA Release 10 (Stata Corporation, College Station, Texas). The main statistical analyses included proportions that were compared for statistical significance, where applicable, using chi-square test. Sample sizes varied by country (100–200) based on the overall national HIV/AIDS prevalence. For any independent variable, with at least 100 study participants evenly divided between 2 categories, there is 80% power to detect a 20% difference when comparing 2 prevalence rates, with a type 1 two-sided error of 5%.
Methods
The AIDS Treatment for Life International Survey (ATLIS) was a multicountry, comparative, cross-sectional survey of people living with HIV in 5 global regions: North America (the United States); Latin American (Brazil); Europe (France, Germany, Italy, Russia, Spain, and the United Kingdom); Asia (Australia and Korea); and Africa (Cote d'Ivoire and South Africa) in January to March 2010, with 100 to 200 enrollees per country. The project was initiated and coordinated by the International Association of Physicians in AIDS Care and governed by an ATLIS Task Force composed of HIV experts from 5 continents. The ATLIS survey fieldwork was conducted from January to March 2010 by Kantar Health, a global health research organization.
A standardized approach to patient recruitment, sampling frame, and recruitment setting was complemented by country-specific adaptations to account for local circumstances. Study eligibility included age more than 17 years, diagnosis of HIV or AIDS, and treatment with ART within the past 5 years. Patients were recruited in health care facilities and in community-based organizations and support groups and administered a 40-minute survey via direct interview or telephone encounter or an online self-administered questionnaire. Monetary incentives were offered to respondents for completion of interviews where customary and varied by country, depending on local practice. The ATLIS protocol, questionnaire, and patient recruitment materials were reviewed and approved by Essex Institutional Review Board, Lebanon, New Jersey, as well as by the research ethics review board in each of the countries involved.
To explore the differences in CVD risk, higher risk of CVD was defined as a diagnosis of heart disease or diabetes or both, or age more than 50, diagnosis of hypercholesterolemia or hypertension, smoking history, and obesity. A lower risk of CVD was defined by no history of heart disease or diabetes and not more than 1 CVD risk factor reported previously.
Data were entered into the study database via the Internet directly following the interviews. Data analyses were performed using STATA Release 10 (Stata Corporation, College Station, Texas). The main statistical analyses included proportions that were compared for statistical significance, where applicable, using chi-square test. Sample sizes varied by country (100–200) based on the overall national HIV/AIDS prevalence. For any independent variable, with at least 100 study participants evenly divided between 2 categories, there is 80% power to detect a 20% difference when comparing 2 prevalence rates, with a type 1 two-sided error of 5%.
Source...